NCT02152332View on ClinicalTrials.gov

A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Healthy
Interventions
DRUG

JNJ-54861911-Therapeutic Dose

JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.

DRUG

JNJ-54861911 - Supratherapeutic Dose

JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.

DRUG

JNJ-54861911-Matched Placebo

JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.

DRUG

Moxifloxacin

Moxifloxacin 400 mg on Day 7 in all treatment sequence.

DRUG

Moxifloxacin Matched Placebo

Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.

Trial Locations (1)

Unknown

Tempe

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02152332 - A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants | Biotech Hunter | Biotech Hunter